Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms
Angelantonio Maglio, Carolina Vitale, Luisa Oriana D’Auria, Valeria Longobardi, Antonio Franzese, Corrado Pelaia, Girolamo Pelaia, Cecilia Calabrese, Alessandro Vatrella · 2026
Read Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms by Angelantonio Maglio, Carolina Vitale, Luisa Oriana D’Auria, Valeria Longobardi, Antonio Franzese, Corrado Pelaia, Girolamo Pelaia, Cecilia Calabrese, Alessandro Vatrella (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13573855.txt.
Description
Angelantonio Maglio and co-authors review an antibody drug that nearly wipes out the white cells driving severe asthma, in a 2026 paper. In severe eosinophilic asthma, eosinophils flood the airways, causing attacks, lung decline, and dependence on steroid tablets. Benralizumab targets the receptor these cells carry and flags them for destruction by immune killer cells, an unusually complete clearance. The review gathers the trial record.
Large trials found attack rates cut by up to about half, and over half of steroid-dependent patients stopped steroids entirely in one study. Breathing capacity improved measurably. Five-year extension data confirmed the benefit held with acceptable safety. The authors discuss where the drug sits as treatment goals shift from controlling asthma to quieting the disease itself, and which patients gain most.
Catalog record
| CREATOR | Angelantonio Maglio, Carolina Vitale, Luisa Oriana D’Auria, Valeria Longobardi, Antonio Franzese, Corrado Pelaia, Girolamo Pelaia, Cecilia Calabrese, Alessandro Vatrella |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |